市場調查報告書
商品編碼
921240

感染疾病治療藥的全球市場:成長,趨勢,及預測

Infectious Disease Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

傳染病藥物全球市場的主要成長要素包括政府和非營利組織的意識提升活動,傳染病的傳播以及增加的研發資金。此外,在預測期內,傳染病流行率的上升預計將增加對藥品的需求並推動整體市場增長。

本報告提供全球感染疾病治療藥市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各疾病·治療藥·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 政府及非營利組織的活動
    • 感染疾病的盛行率增加
    • 研究開發的資金籌措
  • 阻礙市場要素
    • 新興國家的診斷和治療的低滲透率
    • 藥的副作用
  • 波特的五力分析

第5章 市場區隔

  • 各疾病
    • HIV
    • 流感
    • 肝炎
    • 結核
    • 瘧疾
    • 其他
  • 各治療藥物
    • 抗菌劑
    • 抗病毒藥物
    • 驅蟲劑
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • AbbVie Inc
    • Boehringer Ingelheim GmbH
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Janssen Pharmaceutical
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc
    • Sanofi SA
    • 武田藥品工業株式會社

第7章 市場機會及今後趨勢

目錄
Product Code: 67059

The major factors for the growth of the infectious disease drugs market include the rising awareness activities by various government and non-profit organizations, increasing prevalence of infectious diseases, and the rising funding for the research and development.

The rising prevalence of infectious diseases is expected to boost the overall growth of the market over the forecast period. According to the World Health Organization (WHO), it is estimated that in 2018, nearly 37.9 million individuals had HIV, globally. It has been identified that most of this prevalence is in low and middle-income countries, with an estimated 66% living in Sub-Saharan Africa.

Similarly, as per the WHO's 2017 Global Tuberculosis Report, approximately 6.3 million new cases of tuberculosis (TB) were reported in 2016. The report also estimated that the new cases corresponded to 61% of the estimated incidence of 10.4 million TB cases. Thus, rising cases of infectious diseases are expected to increase the demand for infectious drugs resulting in the high growth of the market.

Key Market Trends

Malaria Segment is Expected to Hold a Significant Market Share over the Forecast Period

The high prevalence of malaria and other infections; increasing incidence of these conditions; and rising expenditure on the prevention and diagnosis of infectious diseases are likely to be the key factors responsible for the growth of this market. According to the WHO Report, Africa has been found to have the highest rate of malaria. Therefore, between 2000 and 2015, an expansion of malaria interventions has helped to reduce malaria incidence by 37% globally, and by 42% in Africa.

There are also various initiatives focusing on disease prevention are being undertaken globally. Furthermore, the government, private, and nonprofit organizations are also focusing on increasing the management of these diseases. Hence all these factors are expected to drive the overall market growth.

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest infectious disease drug market owing to the rising prevalence of infectious diseases and the presence of better healthcare infrastructure. As per the Centers for Disease Control and Prevention (CDC), in 2017, a total of 9,093 new cases of tuberculosis (TB) were reported in the United States, representing an incidence rate of 2.8 cases per 100,000 population.

Furthermore, the antibiotic prescription rate is relatively high in the United States. In addition, the trend varies significantly, based on the provider in a particular state. Also, there is a rising prevalence of HIV in the United States and there is a rise in approval for the new disease treatment which is expected to boost the growth of the market. Thus, owing to the all above mentioned factors the market is expected to witness high growth over the forecast period.

Competitive Landscape

The market studied is a fragmented market owing to the presence of various market players. Some of the market players are AbbVie Inc, Boehringer Ingelheim GmbH, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, Merck & Co., Inc., Novartis AG, Pfizer Inc, Sanofi SA, and Takeda Pharmaceutical Company Limited.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Awareness Activities by Various Government and Non-profit Organizations
    • 4.2.2 Increasing Prevalence of Infectious Diseases
    • 4.2.3 Rising Funding for the Research and Development
  • 4.3 Market Restraints
    • 4.3.1 Low Penetration Rates of Diagnosis and Treatment in Developing Countries
    • 4.3.2 Side Effects of the Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease
    • 5.1.1 HIV
    • 5.1.2 Influenza
    • 5.1.3 Hepatitis
    • 5.1.4 Tuberculosis
    • 5.1.5 Malaria
    • 5.1.6 Other
  • 5.2 By Treatment
    • 5.2.1 Antibacterial
    • 5.2.2 Antiviral
    • 5.2.3 Antiparasitic
    • 5.2.4 Other
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Boehringer Ingelheim GmbH
    • 6.1.3 Gilead Sciences, Inc.
    • 6.1.4 GlaxoSmithKline plc
    • 6.1.5 Janssen Pharmaceutical (Johnson & Johnson)
    • 6.1.6 Merck & Co., Inc.
    • 6.1.7 Novartis AG
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Sanofi SA
    • 6.1.10 Takeda Pharmaceutical Company Limited

7 MARKET OPPORTUNITIES AND FUTURE TRENDS